Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Friton, Gabriele; Thompson, Caryn Marie; Karadzovska, Daniela; King, Stephen; King, Jonathan N.

doi:10.1186/s12917-017-1100-x

Table 6 Selected hepatic, hematologic and renal variables at pre-treatment and study exit (mean ± SD)

From: Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Variable (Laboratory reference range)	Time	Robenacoxib (n = 118)			Placebo (n = 119)			P value
		Mean (±SD)	Cases^a		Mean (±SD)	Cases^a
			High	Low		High	Low
Serum
Urea nitrogen, mg/dL (6–31 mg/dL)	Pre-Treatment	18.1 (±7.3)	5	0	18.3 (±6.5)	5	0	0.078
Urea nitrogen, mg/dL (6–31 mg/dL)	Study Exit	14.9 (±4.8)	1	0	13.6 (±4.1)	0	0	0.078
Creatinine, mg/dL (0.5–1.6 mg/dL)	Pre-Treatment	0.91 (±0.25)	2	1	0.96 (±0.28)	2	2	0.763
Creatinine, mg/dL (0.5–1.6 mg/dL)	Study Exit	0.79 (±0.21)	0	5	0.81 (±0.20)	0	1	0.763
Alkaline phosphatase, U/L (5–131 U/L)	Pre-Treatment	141.8 (±239.7)	26	0	112.0 (±214.7)	23	0	0.233
Alkaline phosphatase, U/L (5–131 U/L)	Study Exit	162.1 (±281.5)	30	0	116.4 (±176.3)	21	0	0.233
Alanine aminotransferase, U/L (12–118 U/L)	Pre-Treatment	55.3 (±41.6)	6	0	54.0 (±50.0)	7	1	0.613
Alanine aminotransferase, U/L (12–118 U/L)	Study Exit	53.7 (±49.4)	5	0	59.1 (±101.2)	5	1	0.613
Aspartate aminotransferase, U/L (15–66 U/L)	Pre-Treatment	29.6 (±10.5)	1	1	28.8 (±7.8)	0	1	0.449
Aspartate aminotransferase, U/L (15–66 U/L)	Study Exit	37.5 (±46.6)	6	1	41.7 (±41.3)	11	0	0.449
Total bilirubin, mg/dL (0.1–0.3 mg/dL)	Pre-Treatment	0.14 (±0.06)	1	0	0.15 (±0.05)	0	0	0.431
Total bilirubin, mg/dL (0.1–0.3 mg/dL)	Study Exit	0.15 (±0.07)	3	0	0.15 (±0.07)	2	0	0.431
Total protein, g/dL (5.0–7.4 g/dL)	Pre-Treatment	6.6 (±0.54)	7	0	6.5 (±0.57)	7	0	0.806
Total protein, g/dL (5.0–7.4 g/dL)	Study Exit	6.4 (±0.53)	4	0	6.4 (±0.57)	6	0	0.806
Albumin, g/dL (2.7–4.4 g/dL)	Pre-Treatment	3.6 (±0.34)	0	1	3.6 (±0.34)	0	1	0.501
Albumin, g/dL (2.7–4.4 g/dL)	Study Exit	3.5 (±0.32)	0	1	3.4 (±0.36)	0	2	0.501
Hematology
Hemoglobin, g/dL (12.1–20.3 g/dL)	Pre-Treatment	16.2 (±2.1)	2	3	16.4 (±1.8)	0	1	0.380
Hemoglobin, g/dL (12.1–20.3 g/dL)	Study Exit	15.1 (±1.8)	0	8	15.0 (±1.8)	0	8	0.380
Hematocrit, % (36–60%)	Pre-Treatment	49.8 (±6.4)	5	1	50.2 (±5.5)	2	0	0.302
Hematocrit, % (36–60%)	Study Exit	46.5 (±5.2)	0	5	46.2 (±4.9)	1	1	0.302
Red blood cell count, 10¹²/L (4.8–9.3 10¹²/L)	Pre-Treatment	6.8 (±0.89)	0	0	6.9 (±0.76)	0	0	0.406
Red blood cell count, 10¹²/L (4.8–9.3 10¹²/L)	Study Exit	6.3 (±0.78)	0	2	6.4 (±0.70)	0	0	0.406
White blood cell count, 10⁹/L (4.0–15.5 10⁹/L)	Pre-Treatment	10.9 (±3.7)	13	0	10.4 (±3.0)	6	1	0.454
White blood cell count, 10⁹/L (4.0–15.5 10⁹/L)	Study Exit	13.5 (±4.0)	32	0	13.6 (±4.4)	37	0	0.454
Urine
Urine specific gravity (1.015–1.050)	Pre-Treatment	1.03 (±0.02)	23	8	1.03 (±0.01)	13	15	0.839
Urine specific gravity (1.015–1.050)	Study Exit	1.04 (±0.02)	27	5	1.04 (±0.02)	25	5	0.839

P values were obtained from an analysis of covariance of the study exit values for each variable, with the pre-treatment value for each variable used as a covariate. Only cases for which both pre-treatment and study exit results were available were included in the analysis
^aNumber of cases with values higher and lower than the reference range pre-treatment and at study exit

Back to article page

ISSN: 1746-6148

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Veterinary Research

Contact us